Published in Cancer Res on July 14, 2009
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32
The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 2.85
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood (2013) 1.85
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol Dis (2011) 1.38
The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J Immunol (2011) 1.37
Rictor forms a complex with Cullin-1 to promote SGK1 ubiquitination and destruction. Mol Cell (2010) 1.34
TSC1/TSC2 signaling in the CNS. FEBS Lett (2011) 1.31
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl (2014) 1.23
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21
Mechanism-based treatment in tuberous sclerosis complex. Pediatr Neurol (2013) 1.17
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Tuberous sclerosis complex and Myc coordinate the growth and division of Drosophila intestinal stem cells. J Cell Biol (2011) 1.13
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Hum Mol Genet (2012) 1.10
Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis. EMBO Mol Med (2011) 1.07
Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet (2011) 1.03
Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb Cortex (2012) 0.98
Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Ann Neurol (2012) 0.98
Frontier of epilepsy research - mTOR signaling pathway. Exp Mol Med (2011) 0.95
Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes. J Biol Chem (2011) 0.93
Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation. Mol Cancer Res (2014) 0.89
Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2. Int Rev Cell Mol Biol (2013) 0.86
PI3K regulation of the SKP-2/p27 axis through mTORC2. Oncogene (2012) 0.86
Pml represses tumour progression through inhibition of mTOR. EMBO Mol Med (2011) 0.86
LST8 regulates cell growth via target-of-rapamycin complex 2 (TORC2). Mol Cell Biol (2012) 0.86
Downregulation of protein kinase CK2 induces autophagic cell death through modulation of the mTOR and MAPK signaling pathways in human glioblastoma cells. Int J Oncol (2012) 0.85
Cystogenesis and elongated primary cilia in Tsc1-deficient distal convoluted tubules. Am J Physiol Renal Physiol (2012) 0.85
Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures. Epilepsia (2012) 0.84
Phosphorylation of Rictor at Thr1135 impairs the Rictor/Cullin-1 complex to ubiquitinate SGK1. Protein Cell (2010) 0.82
microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Mol Cancer (2014) 0.79
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget (2015) 0.79
Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells. PLoS One (2015) 0.78
TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity. PLoS One (2013) 0.77
The Role of Embryonic Stem Cell-expressed RAS (ERAS) in the Maintenance of Quiescent Hepatic Stellate Cells. J Biol Chem (2016) 0.76
Cadmium Activates Multiple Signaling Pathways That Coordinately Stimulate Akt Activity to Enhance c-Myc mRNA Stability. PLoS One (2016) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
TOR signaling in growth and metabolism. Cell (2006) 35.29
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet (2002) 7.12
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04
Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer (2007) 5.71
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79
Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J (2003) 4.65
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J (2008) 4.49
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell (2006) 3.83
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci (2005) 3.77
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol (2008) 3.50
Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest (1999) 3.38
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A (2001) 3.01
mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res (2007) 2.44
Molecular organization of target of rapamycin complex 2. J Biol Chem (2005) 2.15
Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol (1998) 2.15
Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol (1997) 1.63
Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol (2003) 1.57
Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia (2007) 1.52
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res (2009) 1.43
Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes. Biochem J (1999) 1.32
In vivo regulation of protein kinase C by trans-phosphorylation followed by autophosphorylation. J Biol Chem (1994) 1.27
TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells. BMC Cancer (2008) 1.18
Identification of different specificity requirements between SGK1 and PKBalpha. FEBS Lett (2005) 1.17
Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression. Cancer Res (2009) 1.02
Overexpression of protein kinase C alpha mRNA in human hepatocellular carcinoma: a potential marker of disease prognosis. Clin Chim Acta (2007) 0.98
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet (2005) 3.94
Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell (2008) 3.91
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol (2008) 3.50
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32
S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell (2006) 3.25
Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol (2013) 3.11
Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab (2011) 2.91
Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science (2013) 2.90
Case records of the Massachusetts General Hospital. Case 36-2006. A 35-year-old pregnant woman with new hypertension. N Engl J Med (2006) 2.84
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One (2009) 2.54
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab (2011) 2.28
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 2.08
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol (2013) 1.73
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol (2013) 1.68
The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell (2006) 1.63
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol (2006) 1.61
Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res (2005) 1.59
The TSC-mTOR pathway regulates macrophage polarization. Nat Commun (2013) 1.57
mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl) (2011) 1.55
Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate (2010) 1.52
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50
A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace (2010) 1.46
Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res (2011) 1.44
Successful localization and treatment for ectopic adrenocorticotrophic hormone secretion in a rare case of possible Tx N2 M0 carcinoid tumor with Cushing syndrome. J Thorac Cardiovasc Surg (2002) 1.38
A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans (2013) 1.37
Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res (2008) 1.31
High-resolution magic angle spinning proton NMR analysis of human prostate tissue with slow spinning rates. Magn Reson Med (2003) 1.29
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer (2010) 1.26
Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nat Biotechnol (2009) 1.21
P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol (2002) 1.21
Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol (2008) 1.16
The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep (2012) 1.16
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.11
Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat (2004) 1.11
Mitotic figure recognition: agreement among pathologists and computerized detector. Anal Cell Pathol (Amst) (2012) 1.09
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol (2004) 1.08
Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol (2014) 1.08
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol (2002) 1.07
Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One (2013) 1.05
Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer (2008) 1.05
Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res (2009) 1.04
Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol (2012) 1.03
Loss of cables protein expression in human non-small cell lung cancer: a tissue microarray study. Hum Pathol (2003) 1.03
Angiomyolipoma have common mutations in TSC2 but no other common genetic events. PLoS One (2011) 0.99
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol (2007) 0.97
Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol (2012) 0.97
Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med (2014) 0.97
Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate (2011) 0.96
MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer (2014) 0.96
Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw (2013) 0.95
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res (2010) 0.95
mTORC1 status dictates tumor response to targeted therapeutics. Sci Signal (2013) 0.95
Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A (2013) 0.95
A decade in prostate cancer: from NMR to metabolomics. Nat Rev Urol (2011) 0.94
Smaller prostate gland size and older age predict Gleason score upgrading. Urol Oncol (2011) 0.94
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). PLoS One (2012) 0.93
Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. Urology (2011) 0.92
Expression of CD147 is associated with prostate cancer progression. Int J Cancer (2011) 0.92
Enantioselective hydrogenation of tetrasubstituted olefins of cyclic beta-(acylamino)acrylates. J Am Chem Soc (2003) 0.91
Highly enantioselective asymmetric hydrogenation of alpha-phthalimide ketone: an efficient entry to enantiomerically pure amino alcohols. J Am Chem Soc (2004) 0.90
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications. J Pathol (2013) 0.89
mTORC1 signaling activates NRF1 to increase cellular proteasome levels. Cell Cycle (2015) 0.89
Interinstitutional whole slide imaging teleconsultation service development: assessment using internal training and clinical consultation cases. Arch Pathol Lab Med (2014) 0.88
Molecular basis of giant cells in tuberous sclerosis complex. N Engl J Med (2014) 0.87
The mammalian target of rapamycin complex 1 regulates leptin biosynthesis in adipocytes at the level of translation: the role of the 5'-untranslated region in the expression of leptin messenger ribonucleic acid. Mol Endocrinol (2008) 0.87
Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation (2002) 0.87
Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning. Magn Reson Med (2005) 0.87
A molecular link between AKT regulation and chemotherapeutic response. Cancer Cell (2009) 0.87
Over-expression of extracellular matrix metalloproteinase inducer in prostate cancer is associated with high risk of prostate-specific antigen relapse after radical prostatectomy. Clin Invest Med (2011) 0.87
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2005. A 59-year-old woman with an incidentally discovered adrenal nodule. N Engl J Med (2005) 0.87
TIP30 is associated with progression and metastasis of prostate cancer. Int J Cancer (2008) 0.86
Case records of the Massachusetts General Hospital. Case 16-2005. A nine-year-old girl with headaches and hypertension. N Engl J Med (2005) 0.86
Chewing the fat on tumor cell metabolism. Cell (2010) 0.86
A close surgical margin after radical prostatectomy is an independent predictor of recurrence. J Urol (2012) 0.86